PT G20210A, factors V G1691A and 1299 His-Arg mutations and tamoxifen-associated thromboembolism in patients with breast cancer.
Eroğlu
Aydan
A
Cam
Ragip
R
Yildiz
Züleyha
Z
Akar
Nejat
N
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000235:genetics*; D015897:Comorbidity; D005165:Factor V / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease / Q000453:epidemiology / Q000235:genetics; D005820:Genetic Testing; D006801:Humans; D008875:Middle Aged; D015995:Prevalence; D011516:Prothrombin / Q000235:genetics*; D013629:Tamoxifen / Q000627:therapeutic use; D013923:Thromboembolism / Q000453:epidemiology* / Q000235:genetics*; D014421:Turkey / Q000453:epidemiology
D000970:Antineoplastic Agents; D013629:Tamoxifen; D005165:Factor V; D011516:Prothrombin